2Hardy RD, Jafri HS, Olsen K, Wordemann M, Hatfield J, Rogers BB, et al. Elevated cytokine and chemokine levels and prolonged pulmonary airflow resistance in a murine Mycoplasma pneumoniae pneumonia model : a microbiologic, histologic, immunologic, and respiratory plethysmographic profile [ J ]. Infec Immun, 2001, 69 (6) :3869-3876.
3Znaor L, Lovric S, Hogan Q, Sapunar D. Association of neural inflammation with hyperalgesia following spinal nerve ligation[ J ]. Croat Med J, 2007, 48(1) :35-42.
4Fanslow WC, Anderson DM, Grabstein KH, Clark EA, Cosman D, Armitage RJ. Soluble forms of CD40 inhibit biologic responses of human B cells[J]. J Immunol, 1992, 149(2) : 655-660.
5Morgan BP, Harris CL. Complement therapeutics; history ang current progress[J]. Mol Immunol, 2003, 40(2-4) : 159-170.
6Wouters D, Wiessenberg HD, Hart M, Bruins P, Voskuyl A, Daha MR, et al. Complex between Clq and C3 or C4: novel and specific markers for classical complement pathway activation[J]. J Immunol Methods, 2005, 298(1-2) :35-45.
8K. Lind,M. W. Benzon,Skov Jensen,W. A. Clyde. A seroepidemiological study of Mycoplasma pneumoniae infections in Denmark over the 50-year period 1946–1995[J] 1997,European Journal of Epidemiology(5):581～586
